Key result
Ivabradine administration supported recovery from cardiogenic shock and improved left-ventricular function in 1 heart transplant patient with tachycardiomyopathy.
Case Report (n=1)
Ivabradine successfully treated cardiogenic shock due to tachycardiomyopathy in a heart transplant patient who deteriorated with beta-blocker therapy.
May aid select post-transplant cases intolerant to beta-blockers; leaves open efficacy and safety in prospective studies.
Tachycardia-induced cardiomyopathy refers to an impairment in left-ventricular function due to chronic or prolonged tachycardia. We describe a heart transplant patient who developed cardiogenic shock due to tachycardia-induced cardiomyopathy. Low-output failure was further aggravated by administration of a short-acting beta-blocker during invasive hemodynamic monitoring. In contrast, heart rate control by administration of increasing doses of ivabradine supported recovery from cardiogenic shock and led to an improvement in the patient's clinical condition as well as left-ventricular function during follow-up.
No takes yet. Share an insight, caveat, or question.
Zwicker et al. (2010) conducted a case report in Cardiogenic shock due to tachycardia-induced cardiomyopathy after heart transplantation (n=1). Ivabradine was evaluated on Recovery from cardiogenic shock and improvement in clinical condition and left-ventricular function. Ivabradine administration supported recovery from cardiogenic shock and improved left-ventricular function in 1 heart transplant patient with tachycardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: